MDMA Companies in Crisis: Politics, Profits, and Public Trust

MDMA-assisted therapy was once considered the frontrunner in the psychedelic renaissance. For years, advocates, researchers, and patients looked to it as the most likely psychedelic treatment to gain FDA approval. But recent events have shaken confidence in the companies leading this movement, raising serious concerns about ethics, politics, and profit motives in psychedelic medicine.

The FDA Rejection: A Major Setback

In early 2024, Lykos Therapeutics (formerly MAPS Public Benefit Corporation) submitted an application to the FDA for MDMA-assisted therapy to treat PTSD. It was a historic moment—the first psychedelic treatment to reach this stage.

But in 2025, the FDA rejected the application. Regulators cited issues with trial methodology, lack of rigorous data, and concerns about the safety protocols in place. For many, it was a crushing blow—not just to the company, but to the broader credibility of psychedelic science.

A Power Shift Raises New Questions

Since the rejection, Antonio Gracias, a billionaire investor with close ties to Elon Musk, has taken control of Lykos. While investors see this as a chance to stabilize the company and push MDMA toward eventual approval, critics worry about conflicts of interest and the growing influence of powerful elites in a space that was originally about healing, community, and accessibility.

The fear is that psychedelic medicine, once rooted in grassroots activism and nonprofit research, is being reshaped by corporate and political agendas. Instead of prioritizing patients and safe access, companies may prioritize shareholders and profit margins.

Why Ethics Matter in Psychedelic Medicine

Unlike conventional pharmaceuticals, psychedelics carry unique risks and require trust. These are powerful compounds that can make people deeply vulnerable during therapy. Allegations of misconduct in psychedelic trials, coupled with questions about financial transparency, threaten to undermine public trust at the very moment psychedelics are on the edge of legitimacy.

Without ethical safeguards, the entire movement risks being defined not by healing but by scandal. And that would hurt patients most of all—especially those with PTSD, who desperately need new options.

The Learn Euphoria Perspective

At Learn Euphoria, we believe that legalization through education means more than teaching about molecules and brain chemistry. It also means fostering conversations about ethics, safety, and responsibility.

The turmoil around MDMA companies is a reminder: the psychedelic renaissance will not succeed on hype alone. It must be built on science, transparency, and integrity. Otherwise, we risk repeating the mistakes of Big Pharma—putting profits ahead of people.

Want to learn more about the cultural, ethical, and scientific history of psychedelics? Explore our Intro to Psychedelics Online Course and discover how these substances are shaping the future of healing—and why responsibility matters more than ever.